Metabolic syndrome, endocrine disruptors and prostate cancer associations: Biochemical and pathophysiological evidences

V. Quagliariello, S. Rossetti, C. Cavaliere, R. Di Palo, E. Lamantia, L. Castaldo, F. Nocerino, G. Ametrano, F. Cappuccio, G. Malzone, M. Montanari, D. Vanacore, F.J. Romano, R. Piscitelli, G. Iovane, M.F. Pepe, M. Berretta, C. D'Aniello, S. Perdonà, P. MutoG. Botti, G. Ciliberto, B.M. Veneziani, F. De Falco, P. Maiolino, M. Caraglia, M. Montella, R.V. Iaffaioli, G. Facchini

Research output: Contribution to journalArticlepeer-review


This review summarizes the main pathophysiological basis of the relationship between metabolic syndrome, endocrine disruptor exposure and prostate cancer that is the most common cancer among men in industrialized countries. Metabolic syndrome is a cluster of metabolic and hormonal factors having a central role in the initiation and recurrence of many western chronic diseases including hormonal-related cancers and it is considered as the world's leading health problem in the coming years. Many biological factors correlate metabolic syndrome to prostate cancer and this review is aimed to focus, principally, on growth factors, cytokines, adipokines, central obesity, endocrine abnormalities and exposure to specific endocrine disruptors, a cluster of chemicals, to which we are daily exposed, with a hormone-like structure influencing oncogenes, tumor suppressors and proteins with a key role in metabolism, cell survival and chemo-resistance of prostate cancer cells. Finally, this review will analyze, from a molecular point of view, how specific foods could reduce the relative risk of incidence and recurrence of prostate cancer or inhibit the biological effects of endocrine disruptors on prostate cancer cells. On the basis of these considerations, prostate cancer remains a great health problem in terms of incidence and prevalence and interventional studies based on the treatment of metabolic syndrome in cancer patients, minimizing exposure to endocrine disruptors, could be a key point in the overall management of this disease.
Original languageEnglish
Pages (from-to)30606-30616
Number of pages11
Issue number18
Publication statusPublished - 2017


  • Cancer
  • Endocrine disruptors
  • Metabolic syndrome
  • Nutrition
  • Prostate
  • 4 hydroxynonenal
  • 4,4' isopropylidenediphenol
  • adipocytokine
  • adiponectin
  • advanced glycation end product
  • chemokine receptor CXCR1
  • chemokine receptor CXCR2
  • cytokine
  • endocrine disruptor
  • endosulphan
  • growth factor
  • high density lipoprotein cholesterol
  • immunoglobulin enhancer binding protein
  • interleukin 6
  • interleukin 8
  • leptin
  • lindane
  • lipid peroxide
  • low density lipoprotein cholesterol
  • macrophage inhibitory cytokine type 1
  • malonaldehyde
  • nonylphenol
  • phthalic acid
  • propoxur
  • prostate specific antigen
  • selenium
  • somatomedin C
  • tumor suppressor protein
  • unclassified drug
  • unindexed drug
  • vitamin D
  • abdominal obesity
  • androgen deprivation therapy
  • APC gene
  • blood brain barrier
  • body mass
  • cancer cell
  • cancer incidence
  • cancer inhibition
  • cancer mortality
  • cancer prognosis
  • cancer recurrence
  • cancer resistance
  • cancer risk
  • carcinogenesis
  • castration resistant prostate cancer
  • cell survival
  • dietary intake
  • disease association
  • DNA methylation
  • DNA modification
  • epithelial mesenchymal transition
  • gene
  • Gleason score
  • GSTP1 gene
  • high risk patient
  • human
  • hypertension
  • inflammation
  • intervention study
  • macrophage
  • metabolic syndrome X
  • metabolism
  • morbidity
  • mortality
  • nutrition
  • obesity
  • oncogene
  • oxidative stress
  • pathophysiology
  • prevalence
  • prostate cancer
  • prostatectomy
  • RASSF1A gene
  • Review
  • waist hip ratio


Dive into the research topics of 'Metabolic syndrome, endocrine disruptors and prostate cancer associations: Biochemical and pathophysiological evidences'. Together they form a unique fingerprint.

Cite this